Portfolio breadth Viatris operates a diversified portfolio across generics, established brands, and innovative medicines, enabling sales teams to offer integrated, end-to-end procurement solutions to hospitals, retail pharmacies, and regional distributors, unlocking cross-sell opportunities across multiple therapeutic areas.

Biosimilars push The company is positioning biosimilars, complex generics, and specialty drugs as growth drivers, presenting opportunities to win tenders and long-term supply agreements with health systems seeking cost-effective, reliable access to high-value biologics and complex products.

Pain therapy momentum FDA accepted Viatris NDA for fast-acting non-opioid meloxicam with a PDUFA goal in late 2026, signaling a potential new high-demand analgesic addition for acute pain management and an entry point for formulary discussions and hospital networks.

Global supply resilience With global centers in the US, China, and India, Viatris emphasizes resilient supply of therapies and scale, creating opportunities to contract for multi-region deployment, risk sharing, and continuity of supply across markets.

Digital backbone A mature technology stack including SAP BI, LIMS, SuccessFactors, Okta, and analytics tools underpins operations, enabling data-driven partnerships, digital collaboration, and enhanced service offerings for contract manufacturing, supply chain optimization, and pharmacovigilance.